



Press release
2008-09-05

Extension of the subscription period in the ongoing rights issue

The Board of Directors of Tripep AB has resolved, due to the current market conditions, to extend the subscription period of the ongoing rights issue until 19 September 2008 inclusive. The extension does not mean that the period for trading in subscription rights will be extended.

For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se

About Tripep

Tripep develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal[®] and a therapeutic vaccine against Hepatitis C, named ChronVac-C[®], plus the RAS[®] technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company's website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.